NCT07559682

Brief Summary

The purpose of this study is to compare the efficacy of selective COX-2 inhibitors{ etoricoxib vs celecoxib )in relieving orthodontic pain , after initial bonding and arch wire insertion.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started May 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 8, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 18, 2025

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

April 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

April 14, 2026

Last Update Submit

April 23, 2026

Conditions

Orthodontic Pain (D013850)

Outcome Measures

Primary Outcomes (1)

  • Pain intensity

    Pain scores will be measured using a 10cm Visual Analogue Scale (VAS) , The Scale consists of a horizontal line anchored by two verbal descriptions where 0 represented '' No Pain '' and 10 represented ''Maximum Pain''. The Score is determined by measuring the distance from left end of the scale to the mark made by the participant.

    1 year

Study Arms (2)

Group A

ACTIVE COMPARATOR

Group A will be given Celecoxib medicine.

Drug: Celecoxib

Group B

ACTIVE COMPARATOR

Group B will be given Etoricoxib medicine.

Drug: Etoricoxib (Treatment Group)

Interventions

CelecoxibDRUG

Group A will be given Celecoxib 50mg once a day.

Group A
Etoricoxib (Treatment Group)DRUG

Group B will be given Etoricoxib 60mg once a day.

Group B

Eligibility Criteria

Age13 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 13 to 30 years
  • Fully erupted permanent dentition excluding third molars
  • Mild crowding (0 -4mm)

You may not qualify if:

  • Active periodontitis
  • Deep cavities or large restorations
  • Previous dental extraction in less than 4 weeks before bonding
  • History of steroid use within last 6 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sharif Medical City Lahore

Lahore, Pakistan

Location

MeSH Terms

Interventions

CelecoxibEtoricoxib

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur CompoundsPyrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyridines

Study Officials

  • Faiza Malik, BDS, FCPS

    Essentia Health

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2026

First Posted

April 30, 2026

Study Start

May 8, 2025

Primary Completion

August 18, 2025

Study Completion

April 30, 2026

Last Updated

April 30, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations

PA(1)